👥
0
🟢
0
China Keytruda Market: How Is Patient Assistance Programs Bridging the Reimbursement Gap?
Patient assistance and access programs for pembrolizumab — the MSD China initiatives bridging the access gap between NRDL-covered indications and out-of-pocket cost for non-covered indications — creates an important commercial market dimension, with the China Keytruda Market reflecting access programs as both humanitarian and commercial strategy enabling patient access while...
0 Yorumlar 0 Paylaşımlar 9 Görüntülenme 0 İncelemeler
Sponsorlu

Ask ME!

Meet @froq — your AI companion for instant answers, smart conversations, creative ideas, and real-time help. Just mention @froq and start chatting. 🚀